HGSI completes Phase IIa KGF enrollment

Human Genome Sciences (HGSI) completed enrollment of more than 80 patients in its U.S. Phase IIa trial of repifermin keratinocyte growth factor-2 (KGF-2) protein to treat ulcerative colitis. The doubl...